Oculis Holding AG (CR5.SG)
- Simply Wall St.
Oculis Holding (NASDAQ:OCS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Oculis to Present at Upcoming September Investor Conferences
ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences: Wells Fargo Healthcare Conference 2024Event dates: September 4-6, 2024Location: Encore Boston Harbor, Boston, MA H.C. Wainwright 26th Annual Global Investment ConferenceEvent dates: September
- GlobeNewswire
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024Pre-NDA meeting with U.S. Food and Drug Administration (FDA) completed in August for once daily OCS-01 for the treatment of post-operative inflammation and pain following ocular surgery; Providing a clear path forward for ND
